131 related articles for article (PubMed ID: 20052920)
1. [Infective endocarditis of staphylococcal etiology: clinical process and antibacterial therapy].
Iakovlev SV; Shcheka DV; Suvorova MP; Sergeeva EV; Cherkasova NA
Antibiot Khimioter; 2009; 54(5-6):59-64. PubMed ID: 20052920
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.
Moreillon P; Bizzini A; Giddey M; Vouillamoz J; Entenza JM
J Antimicrob Chemother; 2012 Mar; 67(3):652-60. PubMed ID: 22167243
[TBL] [Abstract][Full Text] [Related]
4. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.
Heldman AW; Hartert TV; Ray SC; Daoud EG; Kowalski TE; Pompili VJ; Sisson SD; Tidmore WC; vom Eigen KA; Goodman SN; Lietman PS; Petty BG; Flexner C
Am J Med; 1996 Jul; 101(1):68-76. PubMed ID: 8686718
[TBL] [Abstract][Full Text] [Related]
5. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
[TBL] [Abstract][Full Text] [Related]
6. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization.
Andrade-Baiocchi S; Tognim MC; Baiocchi OC; Sader HS
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):149-52. PubMed ID: 12614988
[TBL] [Abstract][Full Text] [Related]
7. [Infective endocarditis due to high level aminoglycoside resistant Enterococcus faecalis and methicillin resistant coagulase-negative staphylococci presenting with rheumatic manifestations].
Pişkin N; Akduman D; Aydemir H; Celebi G; Oztoprak N; Aktaş E
Mikrobiyol Bul; 2008 Jul; 42(3):509-14. PubMed ID: 18822897
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
9. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
10. Development of a mouse model of induced Staphylococcus aureus infective endocarditis.
Gibson GW; Kreuser SC; Riley JM; Rosebury-Smith WS; Courtney CL; Juneau PL; Hollembaek JM; Zhu T; Huband MD; Brammer DW; Brieland JK; Sulavik MC
Comp Med; 2007 Dec; 57(6):563-9. PubMed ID: 18246868
[TBL] [Abstract][Full Text] [Related]
11. Methicillin-resistant Staphylococcus aureus infection with intermediate sensitivity to vancomycin: a case report and literature review.
Schairer J; Sankri-Tarbichi AG; Fairfax MR; Salimnia H; Guzman JA
J Intensive Care Med; 2008; 23(5):338-41. PubMed ID: 18701528
[TBL] [Abstract][Full Text] [Related]
12. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Woods CW; Cheng AC; Fowler VG; Moorefield M; Frederick J; Sakoulas G; Meka VG; Tenover FC; Zwadyk P; Wilson KH
Clin Infect Dis; 2004 Apr; 38(8):1188-91. PubMed ID: 15095227
[TBL] [Abstract][Full Text] [Related]
13. New agents for Staphylococcus aureus endocarditis.
Drees M; Boucher H
Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
[TBL] [Abstract][Full Text] [Related]
14. The first pediatric case of Staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand.
Phongsamart W; Srifeungfung S; Tiensasitorn C; Vanprapar N; Chearskul S; Chokephaibulkit K
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S264-8. PubMed ID: 16856450
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Chambers HF
Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
[TBL] [Abstract][Full Text] [Related]
16. Staphylococcus aureus bacteremia and endocarditis.
Chang FY
J Microbiol Immunol Infect; 2000 Jun; 33(2):63-8. PubMed ID: 10917874
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Dailey CF; Dileto-Fang CL; Buchanan LV; Oramas-Shirey MP; Batts DH; Ford CW; Gibson JK
Antimicrob Agents Chemother; 2001 Aug; 45(8):2304-8. PubMed ID: 11451689
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
